Novo Nordisk to sell weight-loss drug for $499
Digest more
GoodRx offers coupons for reduced prescription drug prices at retail pharmacies. The company says patients will be able to use GoodRx to self-pay for both Ozempic and Wegovy at the $499-per-month price at 70,000 U.S. retail pharmacies.
The healthcare company will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications. Share prices of GoodRx (NASDAQ: GDRX), the American healthcare company and telemedicine service,
GoodRx stock soars after announcing GLP-1 partnership with Novo Nordisk. A Bank of America analyst recommends selling GDRX shares into the strength before they crash again.
Interestingly, Wall Street firms largely believe the former will playout in the long run. According to The Wall Street Journal, the consensus rating on Goodrx Holdings currently sits at “overweight” with price targets going as high as $7.0, indicating potential “upside” of another 35% from here.
Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, jumped 5% through 9:55 a.m. ET Monday on a series of positive announcements for its GLP-1 products.
GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that via a collaboration with Novo Nordisk, all strengths of Ozempic® (semaglutide) and Wegovy® (semaglutide) pens are available to eligible self-paying patients for $499-per-month through GoodRx,
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.
Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other factors working in its favor, including strong results and a solid pipeline.
GoodRx shares are pulling back Tuesday morning. The stock had jumped over 30% Monday after the company announced a new partnership with Novo Nordisk.
2don MSN
Novo Nordisk slashes price of Ozempic in half to $499 for cash-paying, eligible U.S. patients
Who benefits? The reduced price applies to self-paying patients—those without insurance, or whose insurance doesn’t cover Ozempic. More than 70,000 U.S. pharmacies are participating through partnerships with GoodRx and NovoCare, Novo Nordisk’s cash-pay pharmacy.